SC 13G: Sanofi

AI Summary

SC 13G filing by Sanofi.

Risk Assessment

Risk Level: low

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securitie

Filing Documents

• ef20030320_sc13g.htm (SC 13G) — 63KB
• 0001140361-24-028380.txt ( ) — 64KB

From the Filing

SC 13G 1 ef20030320_sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.__)* Inhibrx Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720N103 (CUSIP Number) May 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 45720N103 1 NAMES OF REPORTING PERSONS Sanofi 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION The Republic of France NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 1,157,926 shares 6 SHARED VOTING POWER 0 shares 7 SOLE DISPOSITIVE POWER 1,157,926 shares 8 SHARED DISPOSITIVE POWER 0 shares 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,157,926 shares 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.0% 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO 2 Item 1. (a) Name of Issuer Inhibrx Biosciences, Inc. (b) Address of Issuer's Principal Executive Offices 11025 N. Torrey Pines Road, Suite 140, La Jolla, CA 92037 Item 2. (a) Name of Person Filing Sanofi (b) Address of Principal Business Office or, if none, Residence 46, avenue de la Grande Arme, 75017 Paris, France (c) Citizenship The Republic of France (d) Title of Class of Securities Common Stock, par value $0.0001 per share (e) CUSIP Number 45720N103 Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with 240.13d–1(b)(1)(ii)(J); (k) Group, in accordance with 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d–1(b)(1)(ii)(J), please specify the type of institution:____________________________ 3 Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 1,157,926 shares (b) Percent of class: 8.0%* (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote 1,157,926 shares (ii) Shared power to vote or to direct the vote 0 shares (iii) Sole power to dispose or to direct the disposition of 1,157,926 shares (iv) Shared power to dispose or to direct the disposition of 0 shares * Percent based on 14,475,904 shares of Common Stock outstanding as of May 30, 2024, as disclosed in the Issuer's Form 8-K filed with the SEC on May 30, 2024. Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following . Item 6. Inhibrx, Inc. 1,157,926 shares 8.0% The shares are held of record by Inhibrx, Inc., the Reporting Person's indirect, wholly owned subsidiary. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person The response of the Reporting Person to Item 6 is incorporated herein by reference. Item 8. Identification and Class

View Full Filing

View this SC 13G filing on SEC EDGAR